Targeted therapy of post-transplant lymphoproliferative disease
10.3760/cma.j.cn101070-20191230-01323
- VernacularTitle:移植后淋巴增殖性疾病的靶向药物治疗
- Author:
Yusi WEI
1
;
Yunfei AN
Author Information
1. 重庆医科大学附属儿童医院风湿免疫科，儿童发育疾病研究教育部重点实验室，儿童发育重大疾病国家国际科技合作基地，儿童感染免疫重庆市重点实验室，重庆 400014
- From:
Chinese Journal of Applied Clinical Pediatrics
2020;35(18):1435-1438
- CountryChina
- Language:Chinese
-
Abstract:
Post-transplant lymphoproliferative disease(PTLD) results from the uncontrolled proliferation of lymphocytes after hematopoietic stem cell transplantation and solid organ transplantation.PTLD greatly reduces the survival of both patients and grafts.The treatments for PTLD include reducing the use of immunosuppressive agents, chemotherapy, EB virus-specific cytotoxic T lymphocytes (CTL), B lymphocyte depletion therapy, targeted inhibitors, etc.However, all of them have shortages.Specific biological target drugs aiming at a certain link in the pathogenesis of PTLD show a good curative effect and small adverse reactions, and thus serve as new options for its prevention and treatment.Because of the limited data, clinical studies are still needed to confirm these drugs.In this article, the application of targeted therapy in the treatment of PTLD was summarized.
